Third long-acting injectable antipsychotic using MedinCell’s technology enters preclinical development
July 9, 2019
MedinCell receives 7,5 M€ from the European Bank of Investment (EIB)
July 7, 2019
MedinCell announces 2018/19 fiscal year results
June 4, 2019
Shareholders audioconference and publication of the results for the 2018-2019 financial year, on June 4, 2019
May 22, 2019
MedinCell demonstrates in vivo the efficacy of the first injectable combining surgical anesthesia and 3 days opioid free postoperative pain management
March 11, 2019
MedinCell receives funding for the second formulation phase of its 6-month injectable contraceptive
January 24, 2019
Publication of the 2019 Financial Calendar
January 15, 2019
Publication of the activity report and financial information for the first half-year (April – Sept. 2018)
December 3, 2018
Publication of the activity report and financial information for the first half-year on December 3, 2018
November 27, 2018
Partial exercise of the over-allotment option – Final amount of the share issue increased to €31.4m
November 5, 2018
